专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2015106296A8 ENOLASE 1 (ENO1) COMPOSITIONS AND USES THEREOF 审中-公开
标题翻译： ENOLI 1（ENO1）组合物及其用途
公开(公告)号：WO2015106296A8
公开(公告)日：2015-08-20
申请号：PCT/US2015011276
申请日：2015-01-13
申请人： BERG LLC , UNIV MIAMI , NARAIN NIVEN RAJIN , SARANGARAJAN RANGAPRASAD , VISHNUDAS VIVEK K , GESTA STEPHANE , JING ENXUAN , DAUNERT SYLVIA , DEO SAPNA K , JIMENEZ JOAQUIN JUAN , DIKICI EMRE , DAFTARIAN PIROUZ MOHAMMAD
发明人： NARAIN NIVEN RAJIN , SARANGARAJAN RANGAPRASAD , VISHNUDAS VIVEK K , GESTA STEPHANE , JING ENXUAN , DAUNERT SYLVIA , DEO SAPNA K , JIMENEZ JOAQUIN JUAN , DIKICI EMRE , DAFTARIAN PIROUZ MOHAMMAD
IPC分类号： A61K38/17 , A61K38/46 , A61P3/10
CPC分类号： A61K38/51 , A61K9/0019 , A61K9/0053 , A61K38/00 , A61K47/48246 , A61K47/59 , A61K47/64 , A61K49/0008 , C12N9/88 , C12Q1/54 , C12Y402/01011 , G01N2333/988 , G01N2800/042
摘要： The invention provides compositions comprising Enol for delivery to a muscle. Further, the invention provides a method for normalizing blood glucose in a subject with elevated blood glucose, comprising administering to the subject enolase 1 (Enol), thereby normalizing blood glucose in the subject. The invention also provides methods of treating one or more conditions including impaired glucose tolerance, insulin resistance, pre-diabetes, and diabetes, especially type 2 diabetes in a subject, comprising administering to the subject enolase 1 (Enol), thereby treating the condition in the subject. In certain methods of the invention, the Enol is delivered to muscle.
摘要翻译：本发明提供包含用于递送至肌肉的Enol的组合物。此外，本发明提供了一种用于使患有血糖升高的受试者的血糖正常化的方法，包括给予受试者烯醇化酶1（Enol），从而使受试者的血糖正常化。本发明还提供了治疗一种或多种病症的方法，包括受试者的葡萄糖耐量降低，胰岛素抵抗，前期糖尿病和糖尿病，特别是2型糖尿病，包括给予受试者烯醇化酶1（Enol），从而治疗主题。在本发明的某些方法中，将烯醇递送至肌肉。

2. 发明申请

WO2015054374A3 PERFORIN-2 ACTIVATORS AND INHIBITORS AS DRUG TARGETS FOR INFECTIOUS DISEASE AND GUT INFLAMMATION 审中-公开
标题翻译： PERFORIN-2激动剂和抑制剂作为感染性疾病和胃炎的药物目标
公开(公告)号：WO2015054374A3
公开(公告)日：2015-05-28
申请号：PCT/US2014059675
申请日：2014-10-08
申请人： UNIV MIAMI
发明人： PODACK ECKHARD , MCCORMACK RYAN
IPC分类号： A61K31/4155 , A61P29/00
CPC分类号： A61K38/50 , A61K31/4155 , A61K31/519 , C12Y305/00
摘要： Methods and compositions are provided to modulate the activity of Perforin-2. Provided herein are various components of the Perforin-2 activation pathway. In specific embodiments, inhibitors of the various components of the Perforin-2 activation pathway are provided which may be employed in various methods, including, but not limited to, the diagnosis and treatment of diseases associated with gut inflammation. Methods of screening for Perforin-2 inhibitors are also provided. Further provided are compounds that increase the ubiquitination of Perforin-2 and thereby increase Perforin-2 activity. Various methods for increasing Perforin-2 activity and for the treatment of infectious disease, in particular bacteria and antibiotic-resistant bacteria, are also provided.
摘要翻译：提供方法和组合物以调节Perforin-2的活性。本文提供的是Perforin-2激活途径的各种组分。在具体实施方案中，提供了穿孔蛋白-2激活途径的各种组分的抑制剂，其可以以各种方法使用，包括但不限于诊断和治疗与肠炎症相关的疾病。还提供了筛选Perforin-2抑制剂的方法。还提供了增加Perforin-2泛素化从而增加Perforin-2活性的化合物。还提供了用于增加Perforin-2活性和治疗感染性疾病，特别是细菌和抗生素抗性细菌的各种方法。

3. 发明申请

WO2014152985A1 BIOMARKERS OF PRETERM NECROTIZING ENTEROCOLITIS 审中-公开
标题翻译：生物标志物预处理药物
公开(公告)号：WO2014152985A1
公开(公告)日：2014-09-25
申请号：PCT/US2014028544
申请日：2014-03-14
申请人： CHILDRENS HOSP MEDICAL CENTER , UNIV MIAMI , BOSTON COLLEGE
发明人： MORROW ARDYTHE L , SCHIBLER KURT , KENNEDY MICHAEL A , NEWBURG DAVID S
IPC分类号： G01N33/50
CPC分类号： G01N33/82 , C12Q1/10 , C12Q1/14 , G01N33/6806 , G01N2800/067
摘要： Methods for identifying a preterm infant having or at risk for necrotizing enterocolitis (NEC) based on metabolomics biomarkers in urine samples and/or microbial biomarkers in stool samples. Preterm birth contributes disproportionately to the global burden of morbidity and mortality in infancy. Necrotizing enterocolitis (NEC) is a devastating emergency of preterm infants that affects about 10% of infants born
摘要翻译：基于尿液样本中的代谢组学生物标志物和/或粪便样品中的微生物标志物来鉴定具有坏死性小肠结肠炎（NEC）或具有坏死性小肠结肠炎（NEC）风险的早产儿的方法。早产对婴儿期全球疾病和死亡率的负担不成比例。坏死性小肠结肠炎（NEC）是早产儿的一种毁灭性紧急情况，影响约10％出生于<29周孕龄的婴儿，死亡率约为30％。

4. 发明申请

WO2013049307A3 ENHANCED IMMUNE MEMORY DEVELOPMENT BY APTAMER TARGETED MTOR INHIBITION OF T CELLS 审中-公开
标题翻译： APTAMER T细胞抑制MTOR抑制增强免疫记忆的发育
公开(公告)号：WO2013049307A3
公开(公告)日：2014-04-24
申请号：PCT/US2012057495
申请日：2012-09-27
申请人： UNIV MIAMI , GILBOA ELI
发明人： GILBOA ELI
IPC分类号： A61K48/00 , C07H21/04 , C12N15/11
CPC分类号： C12N15/113 , A61K39/39 , A61K2039/572 , C12N2310/14 , C12N2310/16 , C12N2310/3519 , C12N2310/51
摘要： The disclosure provides compositions for inducing or enhancing immune cell memory. More specifically the compositions provide highly efficient, low toxic and longer lasting protection for treating diseases. The compositions potentiate long-lasting immune memory cells, which are better equipped to provide protective immunity, than the short-lived effector cells generated shortly after vaccination.
摘要翻译：本公开提供了用于诱导或增强免疫细胞记忆的组合物。更具体地说，该组合物为治疗疾病提供高效，低毒和更持久的保护。该组合物加强长效免疫记忆细胞，其比接种后不久产生的短寿命效应细胞更好地提供保护性免疫。

5. 发明申请

WO2013049856A8 RENAL STEM CELLS ISOLATED FROM KIDNEY 审中-公开
标题翻译：从KIDNEY分离的肾小管细胞
公开(公告)号：WO2013049856A8
公开(公告)日：2013-06-27
申请号：PCT/US2012058369
申请日：2012-10-01
申请人： UNIV MIAMI
发明人： HARE JOSHUA M
IPC分类号： C12N5/074 , A61K35/12 , C12N5/02
CPC分类号： A61K35/22 , A61K35/00 , C12N5/0687
摘要： A novel renal precursor cell is identified from kidney tissue. The cell is multipotent capable of forming renal epithelial and endothelial tissues. The cell can be amplified in culture and maintains sternness over multiple passages. This cell fulfills a major unmet need as a cell- based source for kidney regeneration or repair. Treatment of kidney diseases and disorders (e.g., g lomerularpathies and acute tubular necrosis) may be improved thereby.
摘要翻译：从肾组织中鉴定出新的肾前体细胞。细胞是能够形成肾上皮和内皮组织的多能的。细胞可以在培养物中扩增，并保持多次通过的严格状态。该细胞满足主要未满足的需求，作为肾脏再生或修复的基于细胞的来源。因此可以改善肾脏疾病和病症（例如，细胞壁和急性肾小管坏死）的治疗。

6. 发明申请

WO2012154218A3 REDUCING SOLUBLE UROKINASE RECEPTOR IN THE CIRCULATION 审中-公开
标题翻译：在循环中减少可溶性尿素酶受体
公开(公告)号：WO2012154218A3
公开(公告)日：2013-01-03
申请号：PCT/US2012000240
申请日：2012-05-09
申请人： UNIV MIAMI , REISER JOCHEN
发明人： REISER JOCHEN
IPC分类号： A61M1/34 , A61M1/38 , B01D63/00
CPC分类号： A61M1/3486 , A61K35/16 , A61K38/177 , A61M1/3496 , A61M1/362 , A61M1/3672 , A61M1/3679 , A61M1/3687 , C07K14/70596 , G01N33/6872
摘要： Focal segmental glomerulosclerosis (FSGS) is a common cause of proteinuric kidney disease, which comprises both native and transplanted kidneys. Treatment was limited in the past due to the complicated pathogenesis of FSGS, including previously unidentified serum factors. Here, serum soluble urokinase receptor (suPAR) is reported to be elevated in FSGS patients but not in patients with other primary glomerular diseases. Higher pre-transplantation suPAR levels are associated with risk for FSGS recurrence in kidney grafts. Renal disease only develops when suPAR sufficiently activates podocyte ß3 integrin. Thus, disease pathogenesis can be stopped or slowed by ex vivo removal of suPAR from a subject's circulation. Removal may be measured by comparing the level (e.g., amount or concentration) of suPAR before and after such treatment.
摘要翻译：局灶性节段性肾小球硬化（FSGS）是蛋白尿病的常见原因，其包括天然和移植的肾脏。由于FSGS的复杂发病机制，包括以前未知的血清因子，治疗过去受到限制。据报道，血清可溶性尿激酶受体（suPAR）在FSGS患者中升高，但不存在其他原发性肾小球疾病患者。移植前较高的suPAR水平与肾移植中FSGS复发的风险相关。当suPAR足够激活足细胞β3整联蛋白时，肾脏疾病才会发展。因此，通过从对象的循环中离体去除suPAR可以阻止或减缓疾病发病。可以通过比较在这种治疗之前和之后的suPAR的水平（例如，量或浓度）来测量去除。

7. 发明申请

WO2012170918A2 METHODS OF TREATMENT FOR RETINAL DISEASES 审中-公开
标题翻译：治疗前列腺疾病的方法
公开(公告)号：WO2012170918A2
公开(公告)日：2012-12-13
申请号：PCT/US2012041701
申请日：2012-06-08
申请人： UNIV MIAMI , WEN RONG
发明人： WEN RONG
IPC分类号： A61K38/18
CPC分类号： A61K38/18 , C07K14/475 , A61K2300/00
摘要： The present invention provides methods of treating a retinal disorder comprising administering an effective amount of a neurotrophic factor to a subject having the retinal disorder. The neurotrophic factors useful in the invention include mesencephalic astrocyte-derived neurotrophic factor (MANF) and conserved dopamine neurotrophic factor (CDNF). The present invention further comprises pharmaceutical compositions and kits containing MANF and CDNF.
摘要翻译：本发明提供了治疗视网膜疾病的方法，包括向具有视网膜病症的受试者施用有效量的神经营养因子。用于本发明的神经营养因子包括中脑星形胶质细胞衍生的神经营养因子（MANF）和保守的多巴胺神经营养因子（CDNF）。本发明还包含含有MANF和CDNF的药物组合物和试剂盒。

8. 发明申请

WO2011153491A3 AGONISTS OF GROWTH HORMONE RELEASING HORMONE AS EFFECTORS FOR SURVIVAL AND PROLIFERATION OF PANCREATIC ISLETS 审中-公开
标题翻译：生长激素释放激素作为胰岛素生存和增殖的作用的激素
公开(公告)号：WO2011153491A3
公开(公告)日：2012-04-19
申请号：PCT/US2011039162
申请日：2011-06-03
申请人： UNIV MIAMI , US DEPT VETERANS AFFAIRS , SCHALLY ANDREW VICTOR , LUDWIG BARBARA , BORNSTEIN STEFAN , BLOCK NORMAN L
发明人： SCHALLY ANDREW V , LUDWIG BARBARA , BORNSTEIN STEFAN , BLOCK NORMAN L
IPC分类号： A61K38/25 , A61P3/10 , C07K14/60
CPC分类号： C07K14/60 , A61K35/12 , A61K35/39 , A61K38/25
摘要： Agonists of growth hormone releasing hormone promote islet graft growth and proliferation in patients. Methods of treating patients comprise the use of these agonists.
摘要翻译：生长激素释放激素的激动剂促进患者的胰岛移植物生长和增殖。治疗患者的方法包括使用这些激动剂。

9. 发明申请

WO2012009080A2 DEVICE FOR RADIATION-ACTIVATED LOCALIZED DELIVERY OF TREATMENT AGENTS 审中-公开
标题翻译：辐射激活本地化处理剂的装置
公开(公告)号：WO2012009080A2
公开(公告)日：2012-01-19
申请号：PCT/US2011040203
申请日：2011-06-13
申请人： UNIV MIAMI , AHMED MANSOOR M , WU XIAODONG , GUPTA SEEMA , POLLACK ALAN
发明人： AHMED MANSOOR M , WU XIAODONG , GUPTA SEEMA , POLLACK ALAN
IPC分类号： A61K9/48 , A61K47/48 , A61K51/02 , A61M35/00 , A61P35/00
CPC分类号： A61M5/00 , A61K47/6923 , A61M5/14276 , A61M31/00
摘要： The present invention provides for a biocompatible drug delivery device for the targeted treatment of cancer that is implantable within the tumorous cells of a patient. In one embodiment, the device comprises two polarizable elements mechanically coupled by a connecting element. The device also comprises one or more cancer treatment agents. When the polarizable elements are depolarized, such as by the application of ionizing radiation, the two polarizable elements are repelled from each other and release the cancer treatment agent. In another embodiment, one or more treatment agents are expelled from a miniaturized syringe when internal pressure of the device is increased by the production of gas bubbles in response to the application of ionizing radiation.
摘要翻译：本发明提供用于靶向治疗可植入患者的肿瘤细胞内的癌症的生物相容性药物递送装置。在一个实施例中，该装置包括通过连接元件机械耦合的两个可极化元件。该装置还包含一种或多种癌症治疗剂。当可极化元件例如通过施加电离辐射而去极化时，两种可极化元件彼此排斥并释放癌症治疗剂。在另一个实施方案中，当装置的内部压力响应于施加电离辐射而产生气泡而增加时，将一种或多种处理剂从小型化注射器排出。

10. 发明申请

WO2011109459A3 COMPOSITIONS, KITS AND METHODS FOR DETERMINING EFFICACY OF A THERAPEUTIC AGENT AND TREATING HAIR AND SKIN DISEASES 审中-公开
标题翻译：用于测定治疗药物和治疗头发和皮肤病的效果的组合物，试剂盒和方法
公开(公告)号：WO2011109459A3
公开(公告)日：2011-11-10
申请号：PCT/US2011026778
申请日：2011-03-02
申请人： UNIV MIAMI , KEANE ROBERT W , DE RIVERO VACCARI JUAN PABLO , SAWAYA MARTY ELEANOR , DIETRICH W DALTON , BRAMLETT HELEN M
发明人： KEANE ROBERT W , DE RIVERO VACCARI JUAN PABLO , SAWAYA MARTY ELEANOR , DIETRICH W DALTON , BRAMLETT HELEN M
IPC分类号： G01N33/48
CPC分类号： G01N33/6893 , G01N2800/20 , G01N2800/52
摘要： The methods and kits described herein can be used as diagnostic tools to assess if treatments have continuing therapeutic benefits in treating inflammatory skin diseases/disorders such as androgenetic alopecia (AGA) and a host of other skin problems, and for predicting male patiem baldness in a subject (e.g., human), Additionally, compositions and methods described herein can be used as treatments for inflammatory diseases of skin and hair (e.g., AGA) that are regulated by inflannnatory cytokines and inflammasomes. The experiments described herein show that the NLRPI inflammasome regulates inflammation in patients with skin and hair diseases.
摘要翻译：本文描述的方法和试剂盒可用作诊断工具，以评估治疗在治疗炎症性皮肤疾病/病症如雄激素性脱发（AGA）和其他皮肤问题中是否具有持续的治疗益处，并且用于预测男性患者的秃发另外，本文描述的组合物和方法可以用作由炎性细胞因子和炎症细胞调节的皮肤和毛发（例如，AGA）的炎性疾病的治疗。本文所述的实验表明，NLRPI炎症调节皮肤和毛发疾病患者的炎症。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式